Loading...

EDIT EDITAS MEDICINE INC Expansion Plans 8-K Filing

DTS

DT

EDITAS MEDICINE INC

(EDIT)

2025 8-K

Patent Ruling Update

Financial Results Update

Financial Results Update

Therapy Data Released

New Development Candidate

Product Expansion

Other Special Situation

Product Expansion

Product Expansion

Financial Statements

Management Change

Financial Results

Financial Update

Management Change

Workforce Reduction

Bylaw Amendments

Financial Results

Financial Update

License Fee Sale

Earnings Reports

Resignation of Director

Annual Meeting of Stockholders

Earnings Reports

Earnings Reports

License Agreement

Clinical Trial Results

Severance Benefits Plan App...

Earnings Reports

Departure of Directors

Earnings Reports

Public Offering

Clinical Trial Results

Annual Meeting of Stockholders

Appointment of CFO

Earnings Reports

Appointment of Director

Departure of Directors

Earnings Reports

Departure of Directors or C...

External Links:

Editas Medicine, Inc. announced on September 2, 2025, the nomination of EDIT-401 as its lead development candidate for treating high LDL cholesterol, achieving a 90% reduction in levels during preclinical studies. The company expects to file an investigational new drug application by mid-2026, with adequate funding projected into Q2 2027.

AI Assistant

EDITAS MEDICINE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.